Cardiovascular Systems Inc said it received the U.S. health regulator's approval to market its heart device to treat severe accumulation of calcium in coronary arteries, sending its shares up as much as 23 percent.
The device, Diamondback 360 Coronary Orbital Atherectomy System, will be launched immediately, the company said in a statement on Tuesday.
Plaque buildup, including calcium deposits, in arteries reduces blood supply to the heart, leading to coronary artery disease.
The company estimated the U.S. market opportunity for the device to exceed $1.5 billion annually.
CSI shares touched a near six-year high of $27.90 in early trade, but gave up some of their gains to be up at $26.31 on the Nasdaq.
© 2016 Thomson/Reuters. All rights reserved.